Insulin needle free syringes are used for the administration of insulin in patients who are suffering from diabetes. It is one of the relatively newer developments in the healthcare industry and is likely to gain momentum over the next couple of years. According to this report offered, the global insulin needle-free syringes market is expected to exhibit a steep rise in the growth curve over the next couple of years. In fact, the market is also poised to attain a decent valuation in the years to come. New players are expected to enter the insulin needle-free syringes market in the coming years which is poised to intensify the competition among the existing and new players in the years to come. In addition, the expansion of global footprints of the market players also pose growth potential and is expected to drive market growth across the evaluation period.
The exponentially increasing geriatric population is one of the primary factors driving the growth of the insulin needle-free syringes market. This section of the population is more prone to the risk of developing the disease. It has been asserted by the World Health Organization that, by 2050, the geriatric population is expected to exceed 400 million mark. In addition, the increasing prevalence of obesity, CVDs, etc. are also expected to lead the growth of the insulin needle-free syringes market as it leads to diabetes in the younger population. The increasing patient population is poised to boost the growth of the insulin needle-free syringes market over the next couple of years. Also, the changing food patterns, in conjunction with rising adoption of sedentary lifestyle, are likely to affect the trajectory of the insulin needle-free syringes market in the coming years.
Request a Free Sample Report, Click Here @ https://www.wiseguyreports.com/sample-request/4513484-global-insulin-needle-free-syringes-market-growth-2019-2024
Key Players :
Medical International Technologies
Crossject Medical Technology
Activa Brand Products
National Medical Products
On the basis of product type, the insulin needle-free syringes market has been segmented into powder injections and liquid injections.
On the basis of application, the insulin needle-free syringes market has been segmented into hospital, clinics, and others.
The regional evaluation of the global insulin needle-free syringes market spans across – Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). These regional segments are analyzed on the basis of key country-level markets present in the region. Americas has a huge patient population, which is poised to motivate the insulin needle-free syringes market in the region. In addition, the region has a penchant for advanced medical devices and procedures, which also works in favor of the growth of the regional market. The U.S. is poised to contribute massively to the development of the market in the region. Also, the rising healthcare expenditure is anticipated to add to the revenues of the insulin needle-free syringes market in the region.
In October 2019, EMA’s human medicines advisory committee has backed and recommended approval for Eli Lilly’s Baqsimi. It is the first needle-free treatment for low BP in Europe. It ensures that needle free syringes have a bright future in the European market.
Partner Relations & Marketing Manager
Ph: +1 (339) 368 6938 (US)
Ph: +44 208 133 9349 (UK)